<DOC>
	<DOC>NCT03049657</DOC>
	<brief_summary>Clinical trial with an "European Community marked" medical device in patients with ischemic heart disease and clinical indication of coronary revascularization with drug-eluting stent. Clinical follow-up will be done according to this way: first month telephone or face-to-face interview and at 6 ± 1 month an Angiography follow up + OCT (optical coherence tomography) A randomized clinical trial to compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.(non-inferiority design)</brief_summary>
	<brief_title>Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients with clinical or subclinical ischemic heart disease with indication of percutaneous revascularization. "De Novo" lesions ≥ 70% Reference diameters ≥ 2 mm and ≤ 4 mm Accepted participation in the registration with the signing of informed consent Cardiogenic shock Pregnancy Intolerance or allergy to anti platelet or anticoagulant therapy Elective surgical procedure scheduled within 6 months after inclusion in the study Expectancy of life of less than 1 year. Impossibility of doing 1 year clinical followup. Primary angioplasty in patients with killip class IIIIV or mechanical complications. Patient with preprocedure restenosis. Patients who will not be treated all lesions with the Angiolite stent. Total occlusions Truncus disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>